Bristol-Myers Squibb's Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - Argus Press
Bristol-Myers Squibb's Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Argus Press
PRINCETON, N.J.--(BUSINESS WIRE)--Jan 2, 2019--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration ...
Comments
Post a Comment